Fixed-dose acetylsalicylic acid/esomeprazole: a guide to its use to prevent cardiovascular events and reduce peptic ulcer risk
Drugs & Therapy Perspectives, 05/16/2012
Clinical Article
Lyseng–Williamson KA et al. – Fixed–dose acetylsalicylic acid (ASA)/esomeprazole 81 mg/20 mg (Axanum, Aspaxa, Asariex, Onnua) combines the cardiovascular protective effects of low–dose ASA with the gastroprotective effects of the proton pump inhibitor esomeprazole. In two large trials in patients who were receiving low–dose ASA for the prevention of cardiovascular events and who had an increased risk of ulcer development, the incidence of peptic ulcers was significantly lower with the addition of esomeprazole 20 mg/day than with the addition of placebo.
